Harmony Biosciences Holdings, Inc. (HRMY)
| Market Cap | 2.08B |
| Revenue (ttm) | 235.39M |
| Net Income (ttm) | 17.19M |
| Shares Out | 57.01M |
| EPS (ttm) | 0.34 |
| PE Ratio | 108.85 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,972,255 |
| Open | 37.31 |
| Previous Close | 37.10 |
| Day's Range | 36.02 - 37.31 |
| 52-Week Range | 25.09 - 52.74 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 51.33 (+39.5%) |
| Est. Earnings Date | Nov 9, 2021 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvani...
Financial Performance
In 2020, HRMY's revenue was $159.74 million, an increase of 2,564.59% compared to the previous year's $6.00 million. Losses were -$36.94 million, -75.69% less than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is 51.33, which is an increase of 39.52% from the latest price.
News
Harmony Biosciences To Participate In Three Investor Conferences In September
PLYMOUTH MEETING, Pa., Sept. 2, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Harmony Biosciences Stock Is Trading Higher On $330M Financing Deal With Blackstone, Q2 Earning Beat Estimates
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has entered into a $330 million financing collaboration with The Blackstone Group Inc (NYSE: BX). The financing deal includes up to $300 million in debt c...
Harmony Biosciences Reports Second Quarter 2021 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $73.8 Million for Second Quarter 2021 vs. $38 Million for the Same Period in 2020
Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration
PLYMOUTH MEETING, Pa. and NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing inno...
Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other...
PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
John C. Jacobs, President And CEO Of Harmony Biosciences, Named An Ernst & Young (EY) Entrepreneur Of The Year 2021 G...
PLYMOUTH MEEETING, Pa., July 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., July 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
PLYMOUTH MEETING, Pa., June 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9
PLYMOUTH MEETING, Pa., June 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
Harmony Biosciences To Present New Data Analyses For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
PLYMOUTH MEETING, Pa., June 7, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
Harmony Biosciences to Participate in Three Investor Conferences in June
PLYMOUTH MEETING, Pa., May 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
John C. Jacobs, President and CEO of Harmony Biosciences, Joins Life Sciences Pennsylvania Board of Directors
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
Harmony Biosciences Reports First Quarter 2021 Results and Business Updates
WAKIX® (pitolisant) Total Revenue of $59.7 Million for First Quarter 2021
Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More
Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.
Harmony Biosciences To Present WAKIX® (pitolisant) Efficacy and Safety Data at Upcoming 2021 American Psychiatric Ass...
PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("the Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative t...
Harmony Biosciences To Present WAKIX® (Pitolisant) Data At The 2021 AAN Annual Meeting
PLYMOUTH MEETING, Pa., April 12, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
Harmony Biosciences Launches Grant Program To Address Inequities In The Delivery Of Healthcare In Patients With Sleep...
PLYMOUTH MEETING, Pa., April 7, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
4 New Standout Stocks From Goldman Sachs Analysts
Analysts at Goldman Sachs are out with four new Buy recommendations on companies in the oil, biotech and health care businesses.
Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates
WAKIX® (pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020
Harmony Biosciences Hosts Summit Which Sheds Light on Impact of Sleep Disruption in Rare Diseases
PLYMOUTH MEETING, Pa., March 19, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
Harmony Biosciences Highlights Publication of WAKIX® (pitolisant) Efficacy Data in Sleep Medicine
PLYMOUTH MEETING, Pa., March 17, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
Harmony Biosciences Appoints Sandip Kapadia as Chief Financial Officer
PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
Harmony Biosciences Announces Date Of Fourth Quarter And Full Year 2020 Financial Results
PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...